Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High dose mitoxantrone with thiotepa, cyclophosphamide and autologous stem cell rescue for high risk stage II and stage III breast cancer. German GABG-4/EH-93-Study.
Zander AR, Krüger W, Kröger N, Damon L, Königmann M, Berdel WE, Gieseking F, Schäfer-Eckart K, Möbus V, Frickhofen N, Wandt H, Illiger HJ, Metzner B, Kolbe K, Wörmann B, Trümper L, Huber C, Hossfeld DK, Maass H, Jonat W. Zander AR, et al. Among authors: gieseking f. Bone Marrow Transplant. 1996 Sep;18 Suppl 1:S24-5. Bone Marrow Transplant. 1996. PMID: 8899165 Clinical Trial. No abstract available.
Disseminated breast cancer cells prior to and after high-dose therapy.
Krüger WH, Kröger N, Tögel F, Renges H, Badbaran A, Hornung R, Jung R, Gutensohn K, Gieseking F, Jänicke F, Zander AR. Krüger WH, et al. Among authors: gieseking f. J Hematother Stem Cell Res. 2001 Oct;10(5):681-9. doi: 10.1089/152581601753193904. J Hematother Stem Cell Res. 2001. PMID: 11672515
Influence of preharvest tumor cell contamination in bone marrow or blood does not predict resultant tumor cell contamination of granulocyte colony-stimulating factor mobilized stem cells.
Krüger W, Kröger N, Tögel F, Badbaran A, Renges H, Gieseking F, Gutensohn K, Jänicke F, Zander AR. Krüger W, et al. Among authors: gieseking f. J Hematother Stem Cell Res. 2001 Apr;10(2):303-7. doi: 10.1089/15258160151135042. J Hematother Stem Cell Res. 2001. PMID: 11359677
Activity of fulvestrant in HER2-overexpressing advanced breast cancer.
Robertson JFR, Steger GG, Neven P, Barni S, Gieseking F, Nolè F, Pritchard KI, O'Malley FP, Simon SD, Kaufman B, Petruzelka L. Robertson JFR, et al. Among authors: gieseking f. Ann Oncol. 2010 Jun;21(6):1246-1253. doi: 10.1093/annonc/mdp447. Epub 2009 Oct 29. Ann Oncol. 2010. PMID: 19875750 Free article.
Role of TP53 mutations in vulvar carcinomas.
Choschzick M, Hantaredja W, Tennstedt P, Gieseking F, Wölber L, Simon R. Choschzick M, et al. Among authors: gieseking f. Int J Gynecol Pathol. 2011 Sep;30(5):497-504. doi: 10.1097/PGP.0b013e3182184c7a. Int J Gynecol Pathol. 2011. PMID: 21804386
BIRC2 amplification in squamous cell carcinomas of the uterine cervix.
Choschzick M, Tabibzada AM, Gieseking F, Woelber L, Jaenicke F, Sauter G, Simon R. Choschzick M, et al. Among authors: gieseking f. Virchows Arch. 2012 Aug;461(2):123-8. doi: 10.1007/s00428-012-1268-1. Epub 2012 Jun 26. Virchows Arch. 2012. PMID: 22733500
35 results